ICCC — ImmuCell Corporation

ImmuCell Corporation (ICCC) is a biotechnology company listed on NASDAQ. It is led by Michael F. Brigham, based in 56 Evergreen Drive, Portland, ME, United States, 04103, with about 67 employees. ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Latest reported ICCC revenue for 2025-09-30 was $5.5M. Net income was -$139.7K. Revenue was down 14.6% from 2025-06-30 to 2025-09-30. ICCC currently screens at market cap $58.9M.

Use this ICCC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ICCC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ICCC SEC filings page. Lician reads the product cache first so this HTML stays unique to ImmuCell Corporation even when a live quote feed is slow.